Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.60 |
| ▸ | RXRA | P19793 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805849 | 1.00 | PPARG (0.60) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8681649 | 0.89 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8681652 | 0.89 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL7147839 | 0.87 | PPARG (0.72) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8150041 | 0.87 | PPARG (0.72) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8150043 | 0.87 | PPARG (0.72) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8154789 | 0.86 | RXRA (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8154792 | 0.86 | RXRA (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8154784 | 0.86 | RXRA (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17847842 | 0.86 | RXRA (0.46) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2022-04-07 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11186534-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186534-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2021-11-30 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200095184-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2020-03-26 | — | — | US | disclosed |
| US-20200095184-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2020-03-26 | — | — | US | disclosed |
| US-20200048217-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200031795-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3233071-B1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS LLC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2018-07-26 | — | — | US | disclosed |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2018-07-26 | — | — | US | disclosed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-20200031795-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-20200048217-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | PPARG 1654/4885RXRA 62/4885CYP1A2 2536/4885 |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-20180208573-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2746/4885RXRA 156/4885CYP1A2 265/4885 |
| US-20200095184-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-11186534-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885RXRA 62/4885CYP1A2 2536/4885 |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885RXRA 62/4885CYP1A2 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.